Sulzer to acquire drug delivery device developer Haselmeier for €100m

25 August 2020 (Last Updated August 25th, 2020 14:40)

Sulzer has agreed to acquire Swiss-German privately held drug delivery device developer and manufacturer Haselmeier in a deal worth €100m ($118m).

Sulzer to acquire drug delivery device developer Haselmeier for €100m
The acquisition will enable Sulzer to expand its healthcare portfolio and seize growth opportunities in the drug delivery device market. Credit: SulzerAG.

Sulzer has agreed to acquire Swiss-German privately held drug delivery device developer and manufacturer Haselmeier in a deal worth €100m ($118m).

Haselmeier develops and manufactures drug delivery devices, including self-injection pens, indicated for use in reproductive health, growth disorders, osteoporosis and diabetes.

The acquisition is part of Sulzer’s strategy to expand its applicator division, which manufactures devices, including for the beauty, car and healthcare markets.

Furthermore, by integrating the acquired business with its APS division, Sulzer expects to generate cost synergies through insourcing.

Sulzer APS president Girts Cimermans said: “We are excited to welcome the Haselmeier team into the APS family. Haselmeier has a successful track record of providing innovative drug delivery devices based on its proprietary IP business model.

“We believe that we will add to the success story by providing financial strength and precision injection moulding capabilities, thereby accelerating the company’s growth. Furthermore, combining our expertise in liquid mixing applications with Haselmeier’s drug delivery competence will benefit our pharmaceutical customers, providing them with innovative and differentiated devices and services.”

In a separate development, retinal gene therapy company Gyroscope Therapeutics received 510(k) clearance from the US Food and Drug Administration (FDA) for its Orbit Subretinal Delivery System (SDS).

The Orbit SDS is indicated for microinjection into the subretinal space at the back of the eye.

This approach enables access to the subretinal space without the requirement for retinotomy or vitrectomy. The clearance is based on the injection of Balanced Salt Solution (BSS) or BSS PLUS.